Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

The Lustgarten Foundation for Pancreatic Cancer Research Company Profile

19:06 EDT 23rd April 2014 | BioPortfolio

Founded in 1998 by Cablevision executive Marc Lustgarten, with Cablevision chairman Charles Dolan and CEO James Dolan, The Lustgarten Foundation is the nation's largest private, non-profit supporter of pancreatic cancer research, providing more than $20 million to date. The Foundation provides patient information and manages a national public awareness campaign. To learn more and to see Dr. Pausch's PSA, visit www.lustgarten.org.


News Articles [5116 Associated News Articles listed on BioPortfolio]

New SU2C-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team announced

(American Association for Cancer Research) An $8 million grant over three years will fund research focusing on novel immunotherapies for pancreatic cancer.

Holiday Rock & Roll Bash Breaks All-Time Record: More Than $1.95 Million Raised To Benefit The Lustgarten Foundation For Pancreatic Cancer Research

BETHPAGE, N.Y., Dec. 6, 2013 /PRNewswire/ -- On Thursday evening, December 5, Cablevision Systems Corporation (NYSE: CVC), AMC Networks, and The Madison Square Garden Company hosted the thirteent...

Chemotherapy for Pancreatic Cancer, Part 5: Chemotherapy for Metastatic Pancreatic Cancer

Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, discusses the history of and recent developments in chemotherapy for metastatic pancreatic cancer. Chemotherapy for Panc...

Chemotherapy for Pancreatic Cancer, Part 3: Pre-Operative Treatment for Pancreatic Cancer

Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, covers the rationale and evidence for pre-operative (neoadjuvant) therapy for resectable pancreatic cancer. Chemotherapy...

Dr. Matthew Katz on Defining Resectability of Pancreatic Cancer

The third part of surgical oncologist and pancreatic cancer surgeon Matthew Katz’s presentation on pancreatic cancer covered how it is determined whether a patient is a good candidate for the ri...

Chemotherapy for Pancreatic Cancer, Part 6: Moving Forward in Advanced Pancreatic Cancer

Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, reviews novel approaches, including nab-paclitaxel with gemcitabine, in advanced pancreatic cancer. Chemotherapy for Pan...

Advanced Pancreatic Cancer: Changing Landscape Signals Hope

Pancreatic cancer, though relatively uncommon, is the fourth most common of cancer-related deaths. In the United States, 44,030 new cases of pancreatic cancer were diagnosed with 37,660 deaths in 2011...

Chemotherapy for Pancreatic Cancer, Part 2: Resectable vs. Unresectable Pancreatic Cancer

Dr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, reviews the differentiation between resectable and unresectable pancreatic cancer. Chemotherapy for Pancreatic Cancer, P...

PubMed Articles [7226 Associated PubMed Articles listed on BioPortfolio]

Nutrition and pancreatic cancer.

Pancreatic cancer is the fourth leading cause of cancer death in men and women. Prognosis is poor with a 5-year survival rate of less than 5%. As there is no effective screening modality, the best way...

Epigenetic targeting in pancreatic cancer.

The prognosis of pancreatic cancer patients is very poor, with a 5-year survival of less than 6%. Therefore, there is an urgent need for new therapeutic options in pancreatic cancer. In the past years...

Association between Allergies and Risk of Pancreatic Cancer.

Less than 10% of pancreatic cancer cases survive 5 years, yet its etiology is not well understood. Studies suggest allergies are associated with reduced pancreatic cancer risk. Our study collected add...

Synergistic cytotoxic activity of treosulfan and gemcitabine in pancreatic cancer cell lines.

Treatment for advanced pancreatic cancer is still very unsatisfactory. Treosulfan is an alkylating agent used for conventional, as well as high-dose chemotherapy regimens, whereby plasma concentration...

Using digital surveillance to examine the impact of public figure pancreatic cancer announcements on media and search query outcomes.

Background Announcements of cancer diagnoses from public figures may stimulate cancer information seeking and media coverage about cancer. This study used digital surveillance to quantify the effects...

Clinical Trials [3550 Associated Clinical Trials listed on BioPortfolio]

Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer

The purpose of this research study is to try to define the highest doses of temsirolimus and gemcitabine that can be used safely in combination to treat advanced pancreatic cancer. Gemcita...

Safety Study to Determine the Appropriate Dose of Antibody Against Tumor Cells to Best Target Patients With Pancreatic Cancer.

This no treatment research study is being done to find a safe and an appropriate dose of antibody (protein) against tumor cells to best target the cancer in people with pancreatic cancer....

Local Invasion of Pancreatic Cancer

Pancreatic cancer often spreads through local invasion into local structures, including fat, blood vessels, nerves, and nearby organs (stomach, duodenum, spleen, bile duct). Local microsco...

Capecitabine and Radiation Therapy in Advanced Pancreatic Cancer

Pancreatic cancer has traditionally been treated with chemotherapy and radiation therapy with limited results. Preliminary studies of parts of this program in patients with advanced panc...

Study of Combined RHUMAB VEGF and Capecitabine-Based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer

The goal of this clinical research study is to find the highest safe dose of the drug Bevacizumab that can be given in combination with chemoradiation for the treatment of pancreatic cance...

Companies [2258 Associated Companies listed on BioPortfolio]

The Lustgarten Foundation for Pancreatic Cancer Research

Founded in 1998 by Cablevision executive Marc Lustgarten, with Cablevision chairman Charles Dolan and CEO James Dolan, The Lustgarten Foundation is the nation's largest private, non-profit support...

The Lustgarten Foundation

The Lustgarten Foundation, based in Bethpage, New York, is America's largest private foundation dedicated solely to funding pancreatic cancer research. Founded in 1998, the Foundation provides critica...

Sky Foundation, Inc.

After being diagnosed with pancreatic cancer in 2007 and responding well to treatment, Kasselman established Sky Foundation to fund research for the Sky Foundation Pancreatic Cancer Research Fund at t...

Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is the only national organization creating hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure. The organizat...

Pancreatic Cancer Action

About Pancreatic Cancer Action: 5 year survival rates for pancreatic cancer have not changed in over 40 years and it is our mission to change this by way of increased awareness of pancreatic cancer...

More Information about "The Lustgarten Foundation for Pancreatic Cancer Research" on BioPortfolio

We have published hundreds of The Lustgarten Foundation for Pancreatic Cancer Research news stories on BioPortfolio along with dozens of The Lustgarten Foundation for Pancreatic Cancer Research Clinical Trials and PubMed Articles about The Lustgarten Foundation for Pancreatic Cancer Research for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of The Lustgarten Foundation for Pancreatic Cancer Research Companies in our database. You can also find out about relevant The Lustgarten Foundation for Pancreatic Cancer Research Drugs and Medications on this site too.

Search BioPortfolio:
Advertisement

Corporate Database Quicklinks



Searches Linking to this Company Record

Advertisement